Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer

Publisher： Karger

E-ISSN： 1421-9794|61|1|23-31

ISSN： 0009-3157

Source： Chemotherapy, Vol.61, Iss.1, 2015-0, pp. : 23-31

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer

By  

Chemotherapy, Vol. 60, Iss. 2, 2015-02 ,pp. : 129-134

Karger

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy

By Okegawa Takatsugu   Itaya Naoshi   Hara Hidehiko   Tambo Mitsuhiro   Nutahara Kikuo  

International Journal of Molecular Sciences, Vol. 17, Iss. 12, 2016-11 ,pp. : 2008-2008

MDPI

Access to resources Recommend Favorite

Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer

By Amato Robert J.   Glode L. Michael   Podolnick Jeremy   Knight Robert   Crawford David  

Cancers, Vol. 3, Iss. 3, 2011-09 ,pp. : 3449-3460

MDPI

Access to resources Recommend Favorite

Castration-Resistant Prostate Cancer: Targeted Therapies

By  

Chemotherapy, Vol. 57, Iss. 2, 2011-03 ,pp. : 115-127

Karger

Access to resources Recommend Favorite

Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer

By Binder Moritz   Zhang Ben Y.   Hillman David W.   Kohli Rhea   Kohli Tanvi   Lee Adam   Kohli Manish  

International Journal of Molecular Sciences, Vol. 17, Iss. 7, 2016-07 ,pp. : 1097-1097

MDPI

Access to resources Recommend Favorite